MLTXMoonLake Immunotherapeutics AGRunning, no new patients
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Arthritis, Psoriatic
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Oct 15, 2024
- Main results expected
- Jan 4, 2027
- Fully finished
- Sep 13, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)
Measured over: Week 16 compared to placebo
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06641089 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC